Robbins Geller Founding Partner Paul Geller Appointed Co-Lead Counsel in EpiPen Multidistrict Litigation
On September 12, 2017, the Honorable Daniel D. Crabtree of the United States District Court for the District of Kansas issued an order appointing Robbins Geller founding partner Paul J. Geller to the lead counsel team in In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation. The nationwide class action alleges that pharmaceutical company Mylan N.V. and others engaged in anticompetitive and unfair business conduct in its sale and marketing of the EpiPen Auto-Injector device. Plaintiffs allege that Mylan and the other pharmaceutical companies that produce, market and sell the EpiPen engaged in an organized and anticompetitive scheme designed to exclude rivals from the market and systematically and artificially inflated EpiPen prices to unconscionable levels with the price of an EpiPen two-pack skyrocketing to $608.61 from $93.88 in 2007.
After considering submissions and arguments during a hearing on September 7, 2017, the court appointed Geller to the leadership team spearheading the litigation because of his experience in “handling complex litigation including consumer and antitrust class actions.” Geller’s 23 years of litigation experience is indeed broad, and he has led cases in each of Robbins Geller’s practice areas. Recently, Geller was selected to serve in a leadership position on behalf of consumers in the massive Volkswagen “Clean Diesel” Emissions case. This notable appointment came after a record-setting application process in which over 150 attorneys sought the court’s designation as a member of the Plaintiffs’ Steering Committee. The San Francisco legal newspaper The Recorder labeled the group that was ultimately appointed, including Geller, a “class action dream team.” Along with the committee and government agencies, Geller reached a series of settlements on behalf of purchasers, lessees and dealers that total well over $17 billion, the largest settlement in history, concerning illegal CO2 emissions “defeat devices” that Volkswagen installed on many of its diesel-engine vehicles.
In directing this important multidistrict litigation about crucial access to the lifesaving EpiPen, Geller will have the support of Robbins Geller’s many other distinguished consumer and antitrust attorneys, including Stuart A. Davidson, Brian O. O’Mara and Arthur L. Shingler III.
In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, No. 17-md-2785-DDC-TJJ (D. Kan.).